Research Solutions (RSSS) 10-Q 15 May 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 08, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	Research Solutions, Inc.
Entity Central Index Key	0001386301
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	RSSS
Entity Common Stock, Shares Outstanding		24,334,102
Entity Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 5,303,084	$ 4,908,180
Accounts receivable, net of allowance of $100,175 and $115,040, respectively	4,366,975	4,251,251
Prepaid expenses and other current assets	279,376	326,887
Prepaid royalties	740,723	93,336
Total current assets	10,690,158	9,579,654
Other assets:
Property and equipment, net of accumulated depreciation of $781,042 and $749,923, respectively	38,327	59,043
Deposits and other assets	14,397	14,372
Right of use asset, net of accumulated amortization of $241,568 and $155,698, respectively	221,454	307,324
Total assets	10,964,336	9,960,393
Current liabilities:
Accounts payable and accrued expenses	5,734,212	4,686,946
Deferred revenue	2,069,455	1,665,746
Lease liability, current portion	126,780	119,786
Total current liabilities	7,930,447	6,472,478
Long-term liabilities:
Lease liability, long-term portion	112,775	208,513
Total liabilities	8,043,222	6,680,991
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 24,230,661 and 24,016,999 shares issued and outstanding, respectively	24,231	24,017
Additional paid-in capital	23,445,548	22,904,691
Accumulated deficit	(20,442,704)	(19,554,599)
Accumulated other comprehensive loss	(105,961)	(94,707)
Total stockholders' equity	2,921,114	3,279,402
Total liabilities and stockholders' equity	$ 10,964,336	$ 9,960,393

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Allowance for Doubtful Accounts Receivable, Current	$ 100,175	$ 115,040
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 781,042	$ 749,923
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	24,230,661	24,230,661
Common Stock, Shares, Outstanding	24,016,999	24,016,999
Use Rights [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 241,568	$ 155,698

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Total revenue	$ 7,377,957	$ 7,281,508	$ 21,319,320	$ 20,852,568
Cost of revenue:
Total cost of revenue	5,198,296	5,363,144	15,203,464	15,448,895
Gross profit	2,179,661	1,918,364	6,115,856	5,403,673
Operating expenses:
Selling, general and administrative	2,343,161	2,156,097	7,156,937	7,085,102
Depreciation and amortization	9,617	32,768	30,465	119,666
Total operating expenses	2,352,778	2,188,865	7,187,402	7,204,768
Loss from operations	(173,117)	(270,501)	(1,071,546)	(1,801,095)
Other income (expenses):
Interest expense	0	2,000	0	(4,000)
Other income	27,875	13,769	75,124	37,883
Total other income	27,875	15,769	75,124	33,883
Loss from operations before provision for income taxes	(145,242)	(254,732)	(996,422)	(1,767,212)
Provision for income taxes	(5,482)	(10,531)	(22,145)	(32,098)
Loss from continuing operations	(150,724)	(265,263)	(1,018,567)	(1,799,310)
Gain from sale of discontinued operations	33,044	69,277	130,462	205,779
Net loss	(117,680)	(195,986)	(888,105)	(1,593,531)
Other comprehensive income (loss):
Foreign currency translation	(5,216)	(7,385)	(11,254)	(23,051)
Comprehensive loss	$ (122,896)	$ (203,371)	$ (899,359)	$ (1,616,582)
Loss per common share:
Loss per share from continuing operations, basic and diluted	$ 0	$ (0.01)	$ (0.04)	$ (0.08)
Income per share from discontinued operations, basic and diluted	0	0	0	0.01
Net loss per share, basic and diluted	$ 0	$ (0.01)	$ (0.04)	$ (0.07)
Weighted average common shares outstanding, basic and diluted	23,845,798	23,498,796	23,758,844	23,445,569
Platforms [Member]
Revenue:
Total revenue	$ 748,726	$ 489,219	$ 2,005,284	$ 1,290,568
Cost of revenue:
Total cost of revenue	134,672	103,185	365,007	277,534
Transactions [Member]
Revenue:
Total revenue	6,629,231	6,792,289	19,314,036	19,562,000
Cost of revenue:
Total cost of revenue	$ 5,063,624	$ 5,259,959	$ 14,838,457	$ 15,171,361

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Other Comprehensive Loss [Member]
Balance at Jun. 30, 2017	$ 4,344,623	$ 23,883	$ 22,267,327	$ (17,875,858)	$ (70,729)
Balance (in shares) at Jun. 30, 2017		23,883,145
Fair value of vested stock options	176,983	$ 0	176,983	0	0
Fair value of vested restricted common stock	103,026	$ 287	102,739	0	0
Fair value of vested restricted common stock (in shares)		286,647
Repurchase of common stock	(39,672)	$ (35)	(39,637)	0	0
Repurchase of common stock (in shares)		(34,800)
Modification cost of stock options	6,233	$ 0	6,233	0	0
Net loss for the period	(772,965)	0	0	(772,965)	0
Foreign currency translation	(8,951)	0	0	0	(8,951)
Balance at Sep. 30, 2017	3,809,277	$ 24,135	22,513,645	(18,648,823)	(79,680)
Balance (in shares) at Sep. 30, 2017		24,134,992
Balance at Jun. 30, 2017	4,344,623	$ 23,883	22,267,327	(17,875,858)	(70,729)
Balance (in shares) at Jun. 30, 2017		23,883,145
Net loss for the period	(1,593,531)
Foreign currency translation	(23,051)
Balance at Mar. 31, 2018	3,314,756	$ 23,980	22,853,945	(19,469,389)	(93,780)
Balance (in shares) at Mar. 31, 2018		23,980,383
Balance at Jun. 30, 2017	4,344,623	$ 23,883	22,267,327	(17,875,858)	(70,729)
Balance (in shares) at Jun. 30, 2017		23,883,145
Balance at Jun. 30, 2018	3,279,402	$ 24,017	22,904,691	(19,554,599)	(94,707)
Balance (in shares) at Jun. 30, 2018		24,016,999
Balance at Sep. 30, 2017	3,809,277	$ 24,135	22,513,645	(18,648,823)	(79,680)
Balance (in shares) at Sep. 30, 2017		24,134,992
Fair value of vested stock options	212,253	$ 0	212,253	0	0
Fair value of vested restricted common stock	102,313	$ 52	102,261	0	0
Fair value of vested restricted common stock (in shares)		51,655
Repurchase of common stock	(63,283)	$ (52)	(63,231)	0	0
Repurchase of common stock (in shares)		(52,300)
Common stock issued upon exercise of warrants	0	$ 13	(13)	0	0
Common stock issued upon exercise of warrants (in shares)		13,235
Net loss for the period	(624,580)	$ 0	0	(624,580)	0
Foreign currency translation	(6,715)	0	0	0	(6,715)
Balance at Dec. 31, 2017	3,429,265	$ 24,148	22,764,915	(19,273,403)	(86,395)
Balance (in shares) at Dec. 31, 2017		24,147,582
Fair value of vested stock options	49,632	$ 0	49,632	0	0
Fair value of vested restricted common stock	64,708	$ 48	64,660	0	0
Fair value of vested restricted common stock (in shares)		48,305
Forfeited restricted common stock	0	$ (214)	214	0	0
Forfeited restricted common stock (in shares)		(214,324)
Repurchase of common stock	(25,478)	$ (20)	(25,458)	0	0
Repurchase of common stock (in shares)		(19,750)
Common stock issued upon exercise of warrants	0	$ 18	(18)	0	0
Common stock issued upon exercise of warrants (in shares)		18,570
Net loss for the period	(195,986)	$ 0	0	(195,986)	0
Foreign currency translation	(7,385)	0	0	0	(7,385)
Balance at Mar. 31, 2018	3,314,756	$ 23,980	22,853,945	(19,469,389)	(93,780)
Balance (in shares) at Mar. 31, 2018		23,980,383
Balance at Jun. 30, 2018	3,279,402	$ 24,017	22,904,691	(19,554,599)	(94,707)
Balance (in shares) at Jun. 30, 2018		24,016,999
Fair value of vested stock options	39,648	$ 0	39,648	0	0
Fair value of vested restricted common stock	76,261	$ 130	76,131	0	0
Fair value of vested restricted common stock (in shares)		130,127
Repurchase of common stock	(75,200)	$ (34)	(75,166)	0	0
Repurchase of common stock (in shares)		(34,200)
Common stock issued upon exercise of stock options	0	$ 4	(4)	0	0
Common stock issued upon exercise of stock options (in shares)		3,750
Common stock issued upon exercise of warrants	0	$ 39	(39)	0	0
Common stock issued upon exercise of warrants (in shares)		39,000
Net loss for the period	(177,888)	$ 0	0	(177,888)	0
Foreign currency translation	(4,370)	0	0	0	(4,370)
Balance at Sep. 30, 2018	3,137,853	$ 24,156	22,945,261	(19,732,487)	(99,077)
Balance (in shares) at Sep. 30, 2018		24,155,676
Balance at Jun. 30, 2018	$ 3,279,402	$ 24,017	22,904,691	(19,554,599)	(94,707)
Balance (in shares) at Jun. 30, 2018		24,016,999
Common stock issued upon exercise of stock options (in shares)	198,500
Net loss for the period	$ (888,105)
Foreign currency translation	(11,254)
Balance at Mar. 31, 2019	2,921,114	$ 24,231	23,445,548	(20,442,704)	(105,961)
Balance (in shares) at Mar. 31, 2019		24,230,661
Balance at Sep. 30, 2018	3,137,853	$ 24,156	22,945,261	(19,732,487)	(99,077)
Balance (in shares) at Sep. 30, 2018		24,155,676
Fair value of vested stock options	375,795	$ 0	375,795	0	0
Fair value of vested restricted common stock	77,493	$ 20	77,473	0	0
Fair value of vested restricted common stock (in shares)		20,087
Repurchase of common stock	(38,078)	$ (16)	(38,062)	0	0
Repurchase of common stock (in shares)		(15,800)
Common stock issued upon exercise of stock options	0	$ 79	(79)	0	0
Common stock issued upon exercise of stock options (in shares)		79,050
Net loss for the period	(592,537)	$ 0	0	(592,537)	0
Foreign currency translation	(1,668)	0	0	0	(1,668)
Balance at Dec. 31, 2018	2,958,858	$ 24,239	23,360,388	(20,325,024)	(100,745)
Balance (in shares) at Dec. 31, 2018		24,239,013
Fair value of vested stock options	55,795	$ 0	55,795	0	0
Fair value of vested restricted common stock	75,277	$ 12	75,265	0	0
Fair value of vested restricted common stock (in shares)		12,148
Repurchase of common stock	(45,920)	$ (20)	(45,900)	0	0
Repurchase of common stock (in shares)		(20,500)
Net loss for the period	(117,680)	$ 0	0	(117,680)	0
Foreign currency translation	(5,216)	0	0	0	(5,216)
Balance at Mar. 31, 2019	$ 2,921,114	$ 24,231	$ 23,445,548	$ (20,442,704)	$ (105,961)
Balance (in shares) at Mar. 31, 2019		24,230,661

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flow from operating activities:
Net loss	$ (888,105)	$ (1,593,531)
Adjustment to reconcile net loss to net cash provided by (used in) operating activities:
Gain from sale of discontinued operations	(130,462)	(205,779)
Depreciation and amortization	30,465	119,666
Amortization of lease right	85,870	82,537
Fair value of vested stock options	471,238	438,868
Fair value of vested restricted common stock	229,031	270,047
Modification cost of stock options	0	6,233
Changes in operating assets and liabilities:
Accounts receivable	(115,724)	1,129,242
Prepaid expenses and other current assets	177,973	99,788
Prepaid royalties	(647,387)	438,376
Accounts payable and accrued expenses	1,047,266	(1,755,082)
Deferred revenue	403,709	316,685
Lease liability	(88,744)	(82,125)
Net cash provided by (used in) operating activities	575,130	(735,075)
Cash flow from investing activities:
Purchase of property and equipment	(9,107)	(29,284)
Purchase of intangible assets	0	(57,452)
Net cash used in investing activities	(9,107)	(86,736)
Cash flow from financing activities:
Common stock repurchase and retirement	(159,198)	(128,433)
Net cash used in financing activities	(159,198)	(128,433)
Effect of exchange rate changes	(11,921)	(22,401)
Net increase (decrease) in cash and cash equivalents	394,904	(972,645)
Cash and cash equivalents, beginning of period	4,908,180	5,773,950
Cash and cash equivalents, end of period	5,303,084	4,801,305
Supplemental disclosures of cash flow information:
Cash paid for income taxes	22,145	32,098
Cash paid for interest	$ 0	$ 4,000

Organization, Nature of Busines

Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Nature of Business and Basis of Presentation	Note 1. Organization, Nature of Business and Basis of Presentation Organization Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico. Nature of Business We provide two service offerings to our customers: annual licenses that allow customers to access and utilize certain premium features of our cloud based software-as-a-service (“SaaS”) research intelligence platform (“Platforms”) and the transactional sale of published scientific, technical, and medical (“STM”) content managed, sourced and delivered through the Platform (“Transactions”). Platforms and Transactions are packaged as a single solution that enable life science and other research intensive organizations to speed up research and development activities with faster, single sourced access and management of content and data used throughout the intellectual property development lifecycle. Platforms Our cloud-based SaaS research intelligence platform consists of proprietary software and Internet-based interfaces. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information. Additional functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering, identification and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes. Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage. Transactions Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users. Our Platform provides our customers with a single source to the universe of published STM content that includes over 70 million existing STM articles and over one million newly published STM articles each year. Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes. Principles of Consolidation The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2018 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer's financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer's financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros with a US Dollar equivalent of $110,574 and $109,585 at March 31, 2019 and June 30, 2018, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe. The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2019 and 2018. The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2019 and June 30, 2018. The following table summarizes vendor concentrations: Three Months Ended March 31, Nine Months Ended March 31, 2019 2018 2019 2018 Vendor A 16 % 15 % 18 % 14 % Vendor B 12 % 12 % 12 % 12 % Vendor C * * 11 % 11 % * Less than 10% Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”). The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:  identify the contract with a customer;  identify the performance obligations in the contract;  determine the transaction price;  allocate the transaction price to performance obligations in the contract; and  recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured. Deferred Revenue Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue. Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers. Stock-Based Compensation The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Foreign Currency The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $2,302 and $17,307, for the three and nine months ended March 31, 2019, respectively and a gain of $9,737 and $22,609, for the three and nine months ended March 31, 2018. Cash denominated in Euros with a US Dollar equivalent of $110,574 and $109,585 at March 31, 2019 and June 30, 2018, respectively, was held in accounts at financial institutions located in Europe. The following table summarizes the exchange rates used: Nine Months Ended March 31, Year Ended June 30, 2019 2018 2018 2017 Period end Euro : US Dollar exchange rate 1.12 1.23 1.17 1.14 Average period Euro : US Dollar exchange rate 1.15 1.19 1.19 1.09 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05 Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2019 potentially dilutive securities include options to acquire 3,465,335 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 356,759. At March 31, 2018 potentially dilutive securities include options to acquire 3,061,835 shares of common stock, warrants to acquire 1,985,000 shares of common stock and unvested restricted common stock of 434,197. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period. Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2019 and 2018 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. Recently Issued Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Line of Credit

Line of Credit	9 Months Ended
	Mar. 31, 2019
Line of Credit Facility [Abstract]
Line of Credit	Note 3. Line of Credit The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on December 31, 2019, and is subject to certain financial and performance covenants with which we were in compliance as of March 31, 2019. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest at the prime rate plus 2.25% for periods in which we maintain an adjusted quick ratio of 1.3 to 1.0 (the “Streamline Period”), and at the prime rate plus 5.25% when a Streamline Period is not in effect. The interest rate on the line of credit was 6.75% as of March 31, 2019. The line of credit is secured by the Company’s consolidated assets. There were no outstanding borrowings under the line as of March 31, 2019 and June 30, 2018, respectively. As of March 31, 2019, there was approximately $2,227,000 of available credit.

Lease Obligations

Lease Obligations	9 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Lease Obligations	Note 4. Lease Obligations On December 30, 2016, the Company entered into a 48 month non-cancellable lease for its office facilities that will require monthly payments ranging from $10,350 to $11,475 through January 2021. In accounting for the lease, the Company adopted ASU 2016-02, Leases which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the fair value of the lease assets and liability at the inception of the lease was $463,000 using a discount rate of 3.75%. During the nine months ended March 31, 2019, the Company made payments of $88,744 towards the lease liability. As of March 31, 2019 and June 30, 2018, lease liability amounted to $239,555 and $328,299, respectively. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense, including real estate taxes, for the nine months ended March 31, 2019 and 2018 was $108,912 and $105,661, respectively. The right of use asset at June 30, 2018 was $307,324. During the nine months ended March 31, 2019, the Company reflected amortization of right of use asset of $85,870 related to this lease, resulting in a net asset balance of $221,454 as of March 31, 2019.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 5. Stockholders’ Equity Stock Options In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of March 31, 2019, there were 565,129 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan. The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The following table summarizes vested and unvested stock option activity: All Options Vested Options Unvested Options Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at June 30, 2018 2,991,835 $ 1.16 2,885,376 $ 1.15 106,459 $ 1.27 Granted 697,000 2.21 250,000 2.40 447,000 2.10 Options vesting - - 45,959 1.11 (45,959 ) 1.11 Exercised (198,500 ) 1.34 (198,500 ) 1.34 - - Forfeited/Cancelled (25,000 ) 1.05 (16,667 ) 1.05 (8,333 ) 1.05 Outstanding at March 31, 2019 3,465,335 $ 1.36 2,966,168 $ 1.24 499,167 $ 2.03 The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2019 and 2018. Nine Months Ended March 31, 2019 2018 Expected dividend yield 0 % 0 % Risk-free interest rate 2.82% - 3.00 % 1.45% - 2.60 % Expected life (in years) 5 - 6 2.6 - 6 Expected volatility 68% - 69 % 70% - 76 % The weighted average remaining contractual life of all options outstanding as of March 31, 2019 was 5.85 years. The remaining contractual life for options vested and exercisable at March 31, 2019 was 6.05 years. Furthermore, the aggregate intrinsic value of options outstanding as of March 31, 2019 was $2,847,140, and the aggregate intrinsic value of options vested and exercisable at March 31, 2019 was $2,751,308, in each case based on the fair value of the Company’s common stock on March 31, 2019. During the nine months ended March 31, 2019, the Company granted 697,000 options to employees with a fair value of $854,260. The total fair value of options that vested during the nine months ended March 31, 2019 was $471,238 and is included in selling, general and administrative expenses in the accompanying statement of operations. During the nine months ended March 31, 2019, the Company issued 82,800 shares of common stock upon the exercise of 198,500 options on a cashless basis. As of March 31, 2019, the amount of unvested compensation related to stock options was $451,041 which will be recorded as an expense in future periods as the options vest. Additional information regarding stock options outstanding and exercisable as of March 31, 2019 is as follows: Option Exercise Price Options Outstanding Remaining Contractual Life (in years) Options Exercisable $ 0.59 8,150 3.25 8,150 0.60 5,000 3.25 5,000 0.65 6,150 3.25 6,150 0.70 225,000 6.68 225,000 0.77 59,500 4.51 59,500 0.80 16,000 6.39 16,000 0.90 25,667 5.06 25,667 0.97 6,000 3.25 6,000 1.00 215,249 0.75 215,249 1.02 227,000 1.68 227,000 1.05 422,529 7.36 416,362 1.07 53,898 3.55 53,898 1.09 156,165 6.71 156,165 1.10 105,000 6.25 105,000 1.14 3,674 3.25 3,674 1.15 209,400 2.57 209,400 1.20 352,414 8.33 341,414 1.25 32,000 3.88 32,000 1.30 243,000 2.93 243,000 1.50 195,000 3.63 195,000 1.59 35,000 9.12 - 1.75 1,067 3.25 1,067 1.80 140,050 4.15 140,050 1.85 24,000 3.84 24,000 1.95 295,000 9.27 - 1.97 1,422 3.25 1,422 2.40 402,000 9.63 250,000 Total 3,465,335 2,966,168 Warrants The following table summarizes warrant activity: Number of Warrants Weighted Average Exercise Price Outstanding, June 30, 2018 1,985,000 $ 1.25 Granted - - Exercised (100,000 ) 1.22 Expired/Cancelled - - Outstanding, March 31, 2019 1,885,000 $ 1.25 Exercisable, June 30, 2018 1,985,000 $ 1.25 Exercisable, March 31, 2019 1,885,000 $ 1.25 The intrinsic value for all warrants outstanding as of March 31, 2019 was $1,699,500, based on the fair value of the Company’s common stock on March 31, 2019. During the nine months ended March 31, 2019, the Company issued 39,000 shares of common stock upon the exercise of 100,000 warrants on a cashless basis. Additional information regarding warrants outstanding and exercisable as of March 31, 2019 is as follows: Warrant Exercise Price Warrants Outstanding Remaining Contractual Life (in years) Warrants Exercisable $ 1.19 50,000 2.73 50,000 1.25 1,835,000 2.22 1,835,000 Total 1,885,000 1,885,000 Restricted Common Stock Prior to July 1, 2018, the Company issued 1,996,304 shares of restricted common stock to employees valued at $2,031,026, of which 1,365,361 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $1,482,663 has been recognized as an expense. The balance of the non-vested restricted common stock was 416,619 at June 30, 2018. During the nine months ended March 31, 2019, the Company issued an additional 162,362 shares of restricted stock to employees. These shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was $335,709 based on the market price of our common stock ranging from $1.99 to $2.40 per share on the date of grant, which will be amortized over the three-year vesting period. The total fair value of restricted common stock vesting during the nine months ended March 31, 2019 was $229,031 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of March 31, 2019, the amount of unvested compensation related to issuances of restricted common stock was $466,838, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income (loss) per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. The following table summarizes restricted common stock activity: Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, June 30, 2018 416,619 $ 360,160 $ 1.08 Granted 162,362 335,709 2.07 Vested (222,221 ) (229,031 ) 1.01 Forfeited - - - Non-vested, March 31, 2019 356,760 $ 466,838 $ 1.57 Common Stock Repurchase and Retirement Effective as of February 8, 2018, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2018 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $300,000 of outstanding common stock (at prices no greater than $3.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. Effective as of November 13, 2018, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2019 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $300,000 of outstanding common stock (at prices no greater than $3.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. During the nine months ended March 31, 2019, the Company repurchased 70,500 shares of our common stock from employees at an average market price of approximately $2.26 per share for an aggregate amount of $159,198. As of March 31, 2019, $254,080 remains available under the 2019 plan to repurchase common stock from its employees. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

Gain from Sale of Discontinued

Gain from Sale of Discontinued Operations (Reprints and ePrints business line)	9 Months Ended
	Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Gain from Sale of Discontinued Operations (Reprints and ePrints business line)	Note 6. Gain from Sale of Discontinued Operations (Reprints and ePrints business line) On June 30, 2017, we sold the intangible assets of our Reprints and ePrints business pursuant to an Asset Purchase Agreement dated June 20, 2017. The aggregate net consideration for the sale included earn-out payments of 45% of gross margin over the 30-month period subsequent to the closing date. We have made a policy election to record the contingent consideration when the consideration is determined to be realizable (each 6-month period ending subsequent to the closing date). Realizable contingent consideration amounted to $130,462 for the nine months ended March 31, 2019 and is recorded as a gain from the sale of discontinued operations.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 7. Subsequent Events On April 3, 2019, the Company issued 3,441 shares of common stock upon the exercise of 11,000 options on a cashless basis. On April 15, 2019, the Company issued 100,000 shares of common stock upon the exercise of 100,000 options at a price of $1.00 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer's financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer's financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros with a US Dollar equivalent of $110,574 and $109,585 at March 31, 2019 and June 30, 2018, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe. The Company has no customers that represent 10% of revenue or more for the three and nine months ended March 31, 2019 and 2018. The Company has no customers that accounted for greater than 10% of accounts receivable at March 31, 2019 and June 30, 2018. The following table summarizes vendor concentrations: Three Months Ended March 31, Nine Months Ended March 31, 2019 2018 2019 2018 Vendor A 16 % 15 % 18 % 14 % Vendor B 12 % 12 % 12 % 12 % Vendor C * * 11 % 11 % * Less than 10%
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”). The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:  identify the contract with a customer;  identify the performance obligations in the contract;  determine the transaction price;  allocate the transaction price to performance obligations in the contract; and  recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured.
Deferred Revenue	Deferred Revenue Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Cost of Revenue	Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
Foreign Currency	Foreign Currency The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $2,302 and $17,307, for the three and nine months ended March 31, 2019, respectively and a gain of $9,737 and $22,609, for the three and nine months ended March 31, 2018. Cash denominated in Euros with a US Dollar equivalent of $110,574 and $109,585 at March 31, 2019 and June 30, 2018, respectively, was held in accounts at financial institutions located in Europe. The following table summarizes the exchange rates used: Nine Months Ended March 31, Year Ended June 30, 2019 2018 2018 2017 Period end Euro : US Dollar exchange rate 1.12 1.23 1.17 1.14 Average period Euro : US Dollar exchange rate 1.15 1.19 1.19 1.09 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2019 potentially dilutive securities include options to acquire 3,465,335 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 356,759. At March 31, 2018 potentially dilutive securities include options to acquire 3,061,835 shares of common stock, warrants to acquire 1,985,000 shares of common stock and unvested restricted common stock of 434,197. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period. Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2019 and 2018 because all stock options, warrants, and unvested restricted common stock are anti-dilutive.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Concentration of Risk	The following table summarizes vendor concentrations: Three Months Ended March 31, Nine Months Ended March 31, 2019 2018 2019 2018 Vendor A 16 % 15 % 18 % 14 % Vendor B 12 % 12 % 12 % 12 % Vendor C * * 11 % 11 % * Less than 10%
Schedule Of Foreign Currency Exchange Rate	The following table summarizes the exchange rates used: Nine Months Ended March 31, Year Ended June 30, 2019 2018 2018 2017 Period end Euro : US Dollar exchange rate 1.12 1.23 1.17 1.14 Average period Euro : US Dollar exchange rate 1.15 1.19 1.19 1.09 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes vested and unvested stock option activity: All Options Vested Options Unvested Options Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Outstanding at June 30, 2018 2,991,835 $ 1.16 2,885,376 $ 1.15 106,459 $ 1.27 Granted 697,000 2.21 250,000 2.40 447,000 2.10 Options vesting - - 45,959 1.11 (45,959 ) 1.11 Exercised (198,500 ) 1.34 (198,500 ) 1.34 - - Forfeited/Cancelled (25,000 ) 1.05 (16,667 ) 1.05 (8,333 ) 1.05 Outstanding at March 31, 2019 3,465,335 $ 1.36 2,966,168 $ 1.24 499,167 $ 2.03
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the nine months ended March 31, 2019 and 2018. Nine Months Ended March 31, 2019 2018 Expected dividend yield 0 % 0 % Risk-free interest rate 2.82% - 3.00 % 1.45% - 2.60 % Expected life (in years) 5 - 6 2.6 - 6 Expected volatility 68% - 69 % 70% - 76 %
Schedule of Share-based Compensation, by Exercise Price Range	Additional information regarding stock options outstanding and exercisable as of March 31, 2019 is as follows: Option Exercise Price Options Outstanding Remaining Contractual Life (in years) Options Exercisable $ 0.59 8,150 3.25 8,150 0.60 5,000 3.25 5,000 0.65 6,150 3.25 6,150 0.70 225,000 6.68 225,000 0.77 59,500 4.51 59,500 0.80 16,000 6.39 16,000 0.90 25,667 5.06 25,667 0.97 6,000 3.25 6,000 1.00 215,249 0.75 215,249 1.02 227,000 1.68 227,000 1.05 422,529 7.36 416,362 1.07 53,898 3.55 53,898 1.09 156,165 6.71 156,165 1.10 105,000 6.25 105,000 1.14 3,674 3.25 3,674 1.15 209,400 2.57 209,400 1.20 352,414 8.33 341,414 1.25 32,000 3.88 32,000 1.30 243,000 2.93 243,000 1.50 195,000 3.63 195,000 1.59 35,000 9.12 - 1.75 1,067 3.25 1,067 1.80 140,050 4.15 140,050 1.85 24,000 3.84 24,000 1.95 295,000 9.27 - 1.97 1,422 3.25 1,422 2.40 402,000 9.63 250,000 Total 3,465,335 2,966,168
Schedule of Other Share-based Compensation, Activity	The following table summarizes warrant activity: Number of Warrants Weighted Average Exercise Price Outstanding, June 30, 2018 1,985,000 $ 1.25 Granted - - Exercised (100,000 ) 1.22 Expired/Cancelled - - Outstanding, March 31, 2019 1,885,000 $ 1.25 Exercisable, June 30, 2018 1,985,000 $ 1.25 Exercisable, March 31, 2019 1,885,000 $ 1.25
Schedule of Stockholders' Equity Note, Warrants or Rights	Additional information regarding warrants outstanding and exercisable as of March 31, 2019 is as follows: Warrant Exercise Price Warrants Outstanding Remaining Contractual Life (in years) Warrants Exercisable $ 1.19 50,000 2.73 50,000 1.25 1,835,000 2.22 1,835,000 Total 1,885,000 1,885,000
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes restricted common stock activity: Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, June 30, 2018 416,619 $ 360,160 $ 1.08 Granted 162,362 335,709 2.07 Vested (222,221 ) (229,031 ) 1.01 Forfeited - - - Non-vested, March 31, 2019 356,760 $ 466,838 $ 1.57

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Vendor A [Member]
Concentration Risk, Percentage	16.00%	15.00%	18.00%	14.00%
Vendor B [Member]
Concentration Risk, Percentage	12.00%	12.00%	12.00%	12.00%
Vendor C [Member]
Concentration Risk, Percentage	0.00%	0.00%	11.00%	11.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017
Euro to US Dollar [Member]
Period end exchange rate	1.12	1.23	1.17	1.14
Average period exchange rate	1.15	1.19	1.19	1.09
Mexican Peso to US Dollar [Member]
Period end exchange rate	0.05	0.05	0.05	0.05
Average period exchange rate	0.05	0.05	0.05	0.05

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Foreign Currency Transaction Gain (Loss), before Tax	(2,302)	$ 9,737	$ (17,307)	$ 22,609
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			356,759	434,197
Sales Revenue, Net [Member]
Concentration Risk, Percentage			10.00%
Accounts Receivable [Member]
Concentration Risk, Percentage					10.00%
Europe Financial Institutions [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			110,574		109,585
Deposits	$ 110,574		$ 110,574		$ 109,585
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			3,465,335	3,061,835
Employee Stock Option [Member] | Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			1,885,000	1,985,000

Line of Credit (Details Textual

Line of Credit (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jul. 23, 2010	Mar. 31, 2019
Line of Credit Facility, Interest Rate Description		the prime rate plus 5.25%
Line of Credit Facility, Remaining Borrowing Capacity		$ 2,227,000
Line of Credit Facility, Interest Rate at Period End		6.75%
Debt Instrument, Covenant Description		Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt.
Minimum [Member]
Debt Instrument, Covenant Compliance		1.0
Maximum [Member]
Debt Instrument, Covenant Compliance		1.3
Silicon Valley Bank [Member]
Line of Credit Facility, Amount Outstanding	$ 2,500,000
Line Of Credit Facility Expiration Date 1		Dec. 31, 2019
Debt Instrument, Basis Spread on Variable Rate		2.25%
Percentage Of Eligible Accounts Receivable On Line Of Credit	80.00%

Lease Obligations (Details Text

Lease Obligations (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 30, 2016	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Operating Lease Liabilities, Fair Value		$ 463,000
Operating Lease Discount Rate		3.75%
Operating Leases, Rent Expense		$ 108,912	$ 105,661
Amortization of Leased Asset		85,870	$ 82,537
Operating Lease, Payments		88,744
Operating Lease, Liability		239,555		$ 328,299
Other Assets, Noncurrent		$ 221,454		$ 307,324
Minimum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 10,350
Maximum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 11,475

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Mar. 31, 2019$ / sharesshares
Outstanding beginning balance Shares | shares	2,991,835
Granted Shares | shares	697,000
Options vesting Shares | shares	0
Exercised Shares | shares	(198,500)
Forfeited/Cancelled Shares | shares	(25,000)
Outstanding ending balance Shares | shares	3,465,335
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.16
Granted Weighted Average Exercise Price | $ / shares	2.21
Options vesting Weighted Average Exercise Price | $ / shares	0
Exercised Weighted Average Exercise Price | $ / shares	1.34
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	1.05
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.36
Vested Options [Member]
Outstanding beginning balance Shares | shares	2,885,376
Granted Shares | shares	250,000
Options vesting Shares | shares	45,959
Exercised Shares | shares	(198,500)
Forfeited/Cancelled Shares | shares	(16,667)
Outstanding ending balance Shares | shares	2,966,168
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.15
Granted Weighted Average Exercise Price | $ / shares	2.40
Options vesting Weighted Average Exercise Price | $ / shares	1.11
Exercised Weighted Average Exercise Price | $ / shares	1.34
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	1.05
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.24
Unvested Options [Member]
Outstanding beginning balance Shares | shares	106,459
Granted Shares | shares	447,000
Options vesting Shares | shares	(45,959)
Exercised Shares | shares	0
Forfeited/Cancelled Shares | shares	(8,333)
Outstanding ending balance Shares | shares	499,167
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.27
Granted Weighted Average Exercise Price | $ / shares	2.10
Options vesting Weighted Average Exercise Price | $ / shares	1.11
Exercised Weighted Average Exercise Price | $ / shares	0
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	1.05
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 2.03

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Expected dividend yield	0.00%	0.00%
Maximum [Member]
Risk-free interest rate	3.00%	2.60%
Expected life (in years)	6 years	6 years
Expected volatility	69.00%	76.00%
Minimum [Member]
Risk-free interest rate	2.82%	1.45%
Expected life (in years)	5 years	2 years 7 months 6 days
Expected volatility	68.00%	70.00%

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2)	9 Months Ended
	Mar. 31, 2019$ / sharesshares
Options Outstanding	3,465,335
Options Exercisable	2,966,168
Range One [Member]
Option Exercise Price | $ / shares	$ 0.59
Options Outstanding	8,150
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	8,150
Range Two [Member]
Option Exercise Price | $ / shares	$ 0.60
Options Outstanding	5,000
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	5,000
Range Three [Member]
Option Exercise Price | $ / shares	$ 0.65
Options Outstanding	6,150
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	6,150
Range Four [Member]
Option Exercise Price | $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	6 years 8 months 4 days
Options Exercisable	225,000
Range Five [Member]
Option Exercise Price | $ / shares	$ 0.77
Options Outstanding	59,500
Remaining Contractual Life (in years)	4 years 6 months 3 days
Options Exercisable	59,500
Range Six [Member]
Option Exercise Price | $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	6 years 4 months 20 days
Options Exercisable	16,000
Range Seven [Member]
Option Exercise Price | $ / shares	$ 0.90
Options Outstanding	25,667
Remaining Contractual Life (in years)	5 years 21 days
Options Exercisable	25,667
Range Eight [Member]
Option Exercise Price | $ / shares	$ 0.97
Options Outstanding	6,000
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	6,000
Range Nine [Member]
Option Exercise Price | $ / shares	$ 1
Options Outstanding	215,249
Remaining Contractual Life (in years)	9 months
Options Exercisable	215,249
Range Ten [Member]
Option Exercise Price | $ / shares	$ 1.02
Options Outstanding	227,000
Remaining Contractual Life (in years)	1 year 8 months 4 days
Options Exercisable	227,000
Range Eleven [Member]
Option Exercise Price | $ / shares	$ 1.05
Options Outstanding	422,529
Remaining Contractual Life (in years)	7 years 4 months 9 days
Options Exercisable	416,362
Range Twelve [Member]
Option Exercise Price | $ / shares	$ 1.07
Options Outstanding	53,898
Remaining Contractual Life (in years)	3 years 6 months 18 days
Options Exercisable	53,898
Range Thirteen [Member]
Option Exercise Price | $ / shares	$ 1.09
Options Outstanding	156,165
Remaining Contractual Life (in years)	6 years 8 months 15 days
Options Exercisable	156,165
Range Fourteen [Member]
Option Exercise Price | $ / shares	$ 1.10
Options Outstanding	105,000
Remaining Contractual Life (in years)	6 years 3 months
Options Exercisable	105,000
Range Fifteen [Member]
Option Exercise Price | $ / shares	$ 1.14
Options Outstanding	3,674
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	3,674
Range Sixteen [Member]
Option Exercise Price | $ / shares	$ 1.15
Options Outstanding	209,400
Remaining Contractual Life (in years)	2 years 6 months 25 days
Options Exercisable	209,400
Range Seventeen [Member]
Option Exercise Price | $ / shares	$ 1.20
Options Outstanding	352,414
Remaining Contractual Life (in years)	8 years 3 months 29 days
Options Exercisable	341,414
Range Eighteen [Member]
Option Exercise Price | $ / shares	$ 1.25
Options Outstanding	32,000
Remaining Contractual Life (in years)	3 years 10 months 17 days
Options Exercisable	32,000
Range Nineteen [Member]
Option Exercise Price | $ / shares	$ 1.30
Options Outstanding	243,000
Remaining Contractual Life (in years)	2 years 11 months 4 days
Options Exercisable	243,000
Range Twenty [Member]
Option Exercise Price | $ / shares	$ 1.50
Options Outstanding	195,000
Remaining Contractual Life (in years)	3 years 7 months 17 days
Options Exercisable	195,000
Range Twenty One [Member]
Option Exercise Price | $ / shares	$ 1.59
Options Outstanding	35,000
Remaining Contractual Life (in years)	9 years 1 month 13 days
Options Exercisable	0
Range Twenty Two [Member]
Option Exercise Price | $ / shares	$ 1.75
Options Outstanding	1,067
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	1,067
Range Twenty Three [Member]
Option Exercise Price | $ / shares	$ 1.80
Options Outstanding	140,050
Remaining Contractual Life (in years)	4 years 1 month 24 days
Options Exercisable	140,050
Range Twenty Four [Member]
Option Exercise Price | $ / shares	$ 1.85
Options Outstanding	24,000
Remaining Contractual Life (in years)	3 years 10 months 2 days
Options Exercisable	24,000
Range Twenty Five [Member]
Option Exercise Price | $ / shares	$ 1.95
Options Outstanding	295,000
Remaining Contractual Life (in years)	9 years 3 months 7 days
Options Exercisable	0
Range Twenty Six [Member]
Option Exercise Price | $ / shares	$ 1.97
Options Outstanding	1,422
Remaining Contractual Life (in years)	3 years 3 months
Options Exercisable	1,422
Range Twenty Seven [Member]
Option Exercise Price | $ / shares	$ 2.40
Options Outstanding	402,000
Remaining Contractual Life (in years)	9 years 7 months 17 days
Options Exercisable	250,000

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Non-vested, Ending balance	1,885,000
Exercisable	1,885,000
Warrant [Member]
Non-vested, Beginning balance	1,985,000
Granted	0
Exercised	(100,000)
Expired/Cancelled	0
Non-vested, Ending balance	1,885,000	1,985,000
Exercisable	1,885,000	1,985,000
Outstanding, Beginning balance Weighted Average Exercise Price	$ 1.25
Granted Weighted Average Exercise Price	0
Exercised Weighted Average Exercise Price	1.22
Expired/Cancelled Weighted Average Expired Price	0
Outstanding, Ending balance Weighted Average Exercise Price	1.25	$ 1.25
Exercisable, Weighted Average Exercise Price	$ 1.25	$ 1.25

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4)	9 Months Ended
	Mar. 31, 2019$ / sharesshares
Warrants Outstanding	1,885,000
Warrants Exercisable	1,885,000
Range One [Member]
Warrant Exercise Price | $ / shares	$ 1.19
Warrants Outstanding	50,000
Warrants Outstanding Remaining Contractual Life (in years)	2 years 8 months 23 days
Warrants Exercisable	50,000
Range Two [Member]
Warrant Exercise Price | $ / shares	$ 1.25
Warrants Outstanding	1,835,000
Warrants Outstanding Remaining Contractual Life (in years)	2 years 2 months 19 days
Warrants Exercisable	1,835,000

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Non-vested, Ending balance	1,885,000
Restricted Common Stock [Member]
Non-vested, Beginning balance	416,619
Granted Number of shares	162,362
Vested, Number of shares	(222,221)
Forfeited, Number of shares	0	(188,203)
Non-vested, Ending balance	356,760	416,619
Non-vested, Beginning balance	$ 360,160
Granted, Fair Value	335,709
Vested, Fair Value	(229,031)
Forfeited, Fair Value	0	$ 214,324
Non-vested, Ending balance	$ 466,838	$ 360,160
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value	$ 1.08
Granted Weighted Average Grant Date Fair Value	2.07
Vested Weighted Average Grant Date Fair Value	1.01
Forfeited Weighted Average Grant Date Fair Value	0
Non-vested,Ending Balance Weighted Average Grant Date Fair Value	$ 1.57	$ 1.08

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Nov. 13, 2018	Feb. 08, 2018	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Nov. 21, 2017	Nov. 10, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			565,129						565,129			1,874,513
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term									5 years 10 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term									6 years 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 2,847,140						$ 2,847,140
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value			2,751,308						2,751,308
Stock or Unit Option Plan Expense									0	$ 6,233	$ 1,482,663
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			451,041						$ 451,041
Stock Issued During Period, Value, Restricted Stock Award, Gross			75,277	$ 77,493	$ 76,261	$ 64,708	$ 102,313	$ 103,026
Stock Repurchase Program, Authorized Amount	$ 300,000	$ 300,000
Stock Repurchased During Period, Value			45,920	38,078	75,200	25,478	63,283	39,672
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									697,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			55,795	$ 375,795	$ 39,648	$ 49,632	$ 212,253	$ 176,983
Proceeds from Stock Options Exercised									$ 471,238	$ 438,868
Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)									100,000
Intrinsic value of warrant			1,699,500						$ 1,699,500
Treasury Stock Acquired, Average Cost Per Share	$ 3	$ 3
Stock Repurchase Program, Remaining Authorized Repurchase Amount			$ 254,080						$ 254,080
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			1,885,000						1,885,000
Common Stock [Member]
Stock Repurchased During Period, Shares									70,500
Stock Repurchased During Period, Value									$ 159,198
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									82,800
Stock Repurchased Average Price Per Share									$ 2.26
Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)									198,500
Stock Issued During Period, Shares, Conversion of Convertible Securities									39,000
Employees And Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									697,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									$ 854,260
Restricted Stock [Member]
Stock or Unit Option Plan Expense											1,365,361
Stock Issued During Period, Shares, Restricted Stock Award, Gross									162,362
Stock Issued During Period, Value, Restricted Stock Award, Gross									$ 335,709		2,031,026
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value											$ 1,996,304
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period									0		188,203
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Fair Value									$ 0		$ 214,324
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			356,760						356,760		416,619
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value			$ 466,838						$ 466,838		$ 360,160
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Fair Value									$ 229,031
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant													5,000,000
Stock Repurchased Average Price Per Share									$ 1.99
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant													7,000,000
Stock Repurchased Average Price Per Share									$ 2.40

Gain from Sale of Discontinue_2

Gain from Sale of Discontinued Operations (Reprints and ePrints business line) (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		$ 33,044	$ 69,277	$ 130,462	$ 205,779
Reprints and ePrints business line [Member]
Earn-out Income Percentage On Sale Of Intangible Assets	45.00%
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax				$ 130,462

Subsequent Events (Details Text

Subsequent Events (Details Textual) - $ / shares	Apr. 03, 2019	Apr. 15, 2019	Mar. 31, 2019
Sale of Stock, Price Per Share		$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			697,000
Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)			100,000
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,441	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)	11,000	100,000